Physician profile
Paul S Jellinger
NPI 1811900665
$159,188.49
in general payments reported to CMS, 2019-2025
48 companies · $5,243 in 2025
The $5,243 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $25K · 2021: $18K · 2022: $2,431 · 2023: $17K · 2024: $4,439 · 2025: $5,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $4,574 · Travel and Lodging: $1,658 · Consulting Fee: $1,450 · Education: $74.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,391.00 |
| Food and Beverage | $4,574.42 |
| Travel and Lodging | $1,657.73 |
| Consulting Fee | $1,450.00 |
| Education | $74.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41,276.79 | 2019-2025 | Repatha, Tepezza, Evenity |
| Amarin Pharma, INC. | $28,741.79 | 2019-2022 | |
| Esperion Therapeutics, INC. | $19,020.01 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $15,962.94 | 2019-2025 | |
| Corcept Therapeutics | $11,819.42 | 2021-2025 | Korlym |
| Regeneron Healthcare Solutions, INC. | $11,084.02 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $10,976.81 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $9,744.01 | 2019-2021 | |
| Siemens Medical Solutions USA, INC. | $3,617.00 | 2025 | Advia Chemistry Xpt System |
| Novo Nordisk INC | $2,393.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $454.56 | 2019-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $444.62 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $381.18 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $335.47 | 2019-2022 | |
| Dexcom, INC. | $292.51 | 2019-2025 | Dexcom G6 Transmitter |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.57 | 2021-2025 | Jardiance |
| Horizon Therapeutics Plc | $227.78 | 2022-2023 | Tepezza |
| Insulet Corporation | $188.15 | 2019-2024 | Omnipod |
| Abbvie INC. | $161.75 | 2021-2025 | |
| Madrigal Pharmaceuticals | $146.54 | 2025 | Rezdiffra |
| Verity Pharmaceuticals INC. | $138.17 | 2024-2025 | Tlando |
| Ascendis Pharma Endocrinology INC | $131.25 | 2023-2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $121.62 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $100.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.81 | 2021-2023 | |
| Senseonics, Incorporated | $94.00 | 2019 | |
| Shire North American Group INC | $87.05 | 2019 | |
| Medtronic, INC. | $84.63 | 2021-2024 | Minimed 780g |
| Pfizer INC. | $82.32 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $78.98 | 2024 | |
| Lilly USA, LLC | $69.05 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $59.70 | 2019 | |
| Alvogen INC | $53.58 | 2022 | |
| Beta Bionics, INC. | $52.74 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $50.86 | 2021-2025 | Cequr Simplicity |
| Kyowa Kirin, INC. | $49.61 | 2023 | Crysvita |
| Medicure Pharma INC. | $48.74 | 2025 | Zypitamag |
| Ibsa Pharma INC. | $43.84 | 2022-2025 | Licart, Flector, Tirosint |
| Sequel Med Tech, LLC | $36.91 | 2025 | Twiist |
| Tolmar, INC. | $30.23 | 2023 | |
| Lifescan, INC. | $28.58 | 2022 | |
| Grt US Holding, INC. | $26.45 | 2021-2022 | |
| Clarus Therapeutics INC. | $20.44 | 2021 | |
| Amryt Pharma Holdings Ltd | $20.32 | 2023 | Mycapssa |
| Kowa Pharmaceuticals America, INC. | $17.80 | 2024 | Livalo |
| Vivus LLC | $15.84 | 2019 | |
| Recordati_rare_diseases_inc. | $15.50 | 2023 | Isturisa, Signifor Lar |
| Amneal Pharmaceuticals LLC | $14.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.